Xtant Medical Holdings, Inc. - Form 8-K Summary
Business Context and Reporting Period
This Current Report on Form 8-K, dated December 1, 2025, details the completion of two major divestitures by Xtant Medical Holdings, Inc. (the "Company"). The transactions involve the sale of specific assets and a wholly-owned subsidiary to Companion Spine, LLC and its affiliates.
Key Financial Metrics and Transaction Details
- Coflex/CoFix Divestiture: Sale of assets relating to Coflex and CoFix products for a total purchase price of $17.5 million (subject to inventory adjustments).
- Payment Structure (Coflex/CoFix): $7.5 million in prior non-refundable deposits, $1.8 million in cash at closing, and an $8.2 million unsecured promissory note (maturing January 15, 2026).
- Paradigm Divestiture: Sale of 100% of Paradigm Spine GmbH (hardware business outside the U.S.) for $1.7 million in cash at closing (subject to working capital adjustments).
- Debt Reduction: Approximately $8.0 million of net cash proceeds were used to prepay the Company's term loan with MidCap Financial Trust.
- Remaining Debt: $14.4 million outstanding on the term loan as of December 1, 2025, with a potential additional $1.6 million prepayment requirement upon repayment of the Companion Spine Note.
Material Changes Versus Prior Period
The Company has exited its Coflex/CoFix product lines and its non-U.S. hardware business (Paradigm Spine GmbH). These divestitures represent a significant contraction of the Company's asset base and product portfolio compared to the prior period. The filing includes unaudited pro forma financial information reflecting these changes as if they occurred on September 30, 2025, and December 31, 2024, though actual results may differ.
Outlook, Risks, and Contingencies
- Valuation Adjustments: The final purchase prices for both divestitures are subject to adjustments based on closing inventory valuation (Coflex/CoFix) and net working capital/cash/indebtedness (Paradigm). Decreases in the Paradigm price may reduce the principal of the Companion Spine Note or require cash repayment by the Company.
- Pro Forma Limitations: The provided pro forma financial statements are for illustrative purposes only, based on preliminary estimates, and do not reflect all expected future costs.
- Debt Covenants: The term loan agreement with MidCap Financial Trust includes provisions requiring further prepayments contingent on the repayment of the promissory note received from Companion Spine.
Investor Verification Checklist
- Verify the final purchase price adjustments for both the Coflex/CoFix and Paradigm divestitures once closing inventory and working capital calculations are finalized.
- Review the full text of the Asset Purchase Agreement and Equity Purchase Agreement (Exhibits 2.1, 2.2, 2.3, and 2.4) for specific terms regarding indemnification and future obligations.
- Assess the impact of the $8.2 million promissory note on future cash flows and the likelihood of the additional $1.6 million debt prepayment trigger.
- Examine the unaudited pro forma financial statements (Exhibit 99.1) to understand the projected financial position post-divestiture.